Ikena Oncology, Inc. (https://ikenaoncology.com/ Boston, MA, USA; CEO Mark Manfredi, Ikena Oncology) debuted as a public company, listing its shares on the NASDAQ market on March 26, 2021. Ikena Oncology is currently developing AskAt’s EP4 antagonist, AAT-007, for immuno oncology therapy in the US. For further details, please see Ikena’s announcement (Ikena Oncology Public Offering).

About Ikena Oncology

Ikena Oncology is a targeted oncology company developing therapies focused on key signaling pathways that drive cancer. Ikena Oncology licensed AskAt’s EP4 antagonist, AAT-007 and AAT-008, and is currently investigating IK-007 (AAT-007) in a Phase 1b clinical trial in combination with Merck’s anti-PD-1 antibody KEYTRUDA® (pembrolizumab). The trial is targeting patients with advanced or progressive microsatellite stable (MSS) CRC (NCT03658772), which represents approximately 80% of all patients with CRC.